Recent Investment Analysts’ Ratings Changes for Apogee Therapeutics (APGE)
by Scott Moore · The Cerbat GemApogee Therapeutics (NASDAQ: APGE) has recently received a number of price target changes and ratings updates:
- 1/7/2026 – Apogee Therapeutics had its “buy” rating reaffirmed by analysts at Craig Hallum. They now have a $116.00 price target on the stock.
- 1/7/2026 – Apogee Therapeutics is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.
- 1/6/2026 – Apogee Therapeutics was given a new $137.00 price target on by analysts at BTIG Research.
- 1/6/2026 – Apogee Therapeutics had its “outperform” rating reaffirmed by analysts at Royal Bank Of Canada.
- 1/6/2026 – Apogee Therapeutics was given a new $133.00 price target on by analysts at Stifel Nicolaus.
- 1/5/2026 – Apogee Therapeutics had its price target raised by analysts at BTIG Research from $115.00 to $128.00. They now have a “buy” rating on the stock.
- 12/16/2025 – Apogee Therapeutics is now covered by analysts at Stephens. They set an “overweight” rating and a $95.00 price target on the stock.
- 12/16/2025 – Apogee Therapeutics was upgraded by analysts at Stephens to a “strong-buy” rating.
- 12/9/2025 – Apogee Therapeutics is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a “buy” rating and a $103.00 price target on the stock.
- 12/6/2025 – Apogee Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
- 11/15/2025 – Apogee Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
Insiders Place Their Bets
In other news, insider Carl Dambkowski sold 10,900 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $75.00, for a total value of $817,500.00. Following the transaction, the insider directly owned 271,108 shares in the company, valued at approximately $20,333,100. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $75.38, for a total transaction of $1,507,600.00. Following the completion of the transaction, the chief executive officer directly owned 1,212,987 shares of the company’s stock, valued at $91,434,960.06. This trade represents a 1.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 101,685 shares of company stock worth $7,179,630. Insiders own 42.77% of the company’s stock.
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.